

# StageZero to Issue Q2 2021 Financial Results and Hold Conference Call on Tuesday, August 17

written by Raj Shah | August 12, 2021

August 11, 2021 ([Source](#)) – StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS) today announced that it will release its second quarter 2021 operational results before the market open on Tuesday, August 17, 2021. StageZero’s Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EST on Tuesday, August 17, 2021, to review the operational results and discuss business developments.

## Analyst and Investor Call

**Event Date:** Tuesday, August 17, 2021

**Time:** 8:30 a.m. EST

**Webcast Link:** <https://www.webcaster4.com/Webcast/Page/2082/42373>

**Participant Numbers:** Toll Free: +1 844-602-0380

**International:** +1-862-298-0970

**Replay Number:** Toll Free: +1-877-481-4010

**International:** +1-919-882-2331

**Replay Passcode:** 42373

## About StageZero Life Sciences Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company’s next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single

sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit [www.stagezerolifesciences.com](http://www.stagezerolifesciences.com).

**STAGEZERO LIFE SCIENCES LTD.**

James Howard-Tripp  
Chairman & CEO

For further information please contact:  
Rebecca Greco

**Investor Relations**

Tel: 1-855-420-7140 ext. 1838  
[rgreco@stagezerols.com](mailto:rgreco@stagezerols.com)

**SOURCE:** StageZero Life Sciences Ltd